← All trials
NCT04810962
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Feb 28, 2022
- First posted
- Mar 23, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 370
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Formosa Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.